TP53 and diffuse large B-cell lymphoma: Combined treatment of DLBCL cells with HDACi such as vorinostat in combination with the Sirtuin inhibitor niacinamide produced synergistic cytotoxicity in vitro and in vivo by inhibiting BCL6 and activating TP53 [389].